Orthofix Medical, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US68752M1080
USD
15.90
0.18 (1.15%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Orthofix Medical, Inc. stock-summary
stock-summary
Orthofix Medical, Inc.
Pharmaceuticals & Biotechnology
Orthofix Medical Inc., formerly Orthofix International N.V., is a global medical device company. The Company is focused on providing reconstructive and regenerative orthopedic and spine solutions to physicians. The company operates in four segments: BioStim, Biologics, Extremity Fixation and Spine Fixation. Its BioStim solutions products include Cervical-Stim, Spinal-Stim and Physio-Stim. The Biologics products include AlloQuent Structural Allografts, Trinity ELITE, Trinity Evolution and VersaShield. The Extremity Fixation products include Fixator, Eight-Plate Guided Growth System and Contours VPS Volar Plating System III. The Spine Fixation products include Hallmark Anterior Cervical Plate System, Ascent LE Posterior Occipital Cervico-Thoracic (POCT) System, Firebird Deformity Correction System, Phoenix Minimally Invasive Spinal Fixation System, LONESTAR Cervical Stand Alone (CSA), SKYHAWK Lateral Interbody Fusion System & Lateral Plate System and CENTURION POCT System.
Company Coordinates stock-summary
Company Details
3451 Plano Pkwy , LEWISVILLE TX : 75056-9453
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 55 Schemes (34.71%)

Foreign Institutions

Held by 79 Foreign Institutions (6.63%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Ronald Matricaria
Independent Chairman of the Board
Mr. Jon Serbousek
President, Chief Executive Officer, Director
Mr. Jason Hannon
Independent Director
Mr. James Hinrichs
Independent Director
Mr. Alexis Lukianov
Independent Director
Ms. Lilly Marks
Independent Director
Mr. Michael Paolucci
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
203 Million
(Quarterly Results - Jun 2025)
Net Profit:
-14 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 581 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.20

stock-summary
Return on Equity

-26.60%

stock-summary
Price to Book

1.27